Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel O Persky

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
The Lancet. Haematology|February 4, 2018
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre studyPaul M Barr, Hongli Li, W Richard Burack, et al.
American Journal of Hematology|December 22, 2017
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806Daniel O Persky, Hongli Li, Lisa M Rimsza, et al.
Haematologica|February 24, 2018
Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohortLisa M Rimsza, Hongli Li, Rita M Braziel, et al.
Haematologica|July 14, 2022
Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001Deborah M Stephens, Hongli Li, Louis S Constine, et al.
The Oncologist|July 27, 2019
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet NeedsMatthew J Matasar, Stefano Luminari, Paul M Barr, et al.
Blood|November 15, 2014
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313Daniel O Persky, Thomas P Miller, Joseph M Unger, et al.
Haematologica|April 10, 2010
Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphomaChristopher J Stasik, Hiroaki Nitta, Wenjun Zhang, et al.
Leukemia & Lymphoma|January 14, 2016
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520Soham D Puvvada, Hongli Li, Lisa M Rimsza, et al.
Journal of the National Cancer Institute|January 2, 2017
Hodgkin Lymphoma: Current Status and Clinical Trial RecommendationsCatherine S Diefenbach, Joseph M Connors, Jonathan W Friedberg, et al.
Blood|June 12, 2008
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOPLisa M Rimsza, Michael L Leblanc, Joseph M Unger, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
The Lancet. Haematology|February 4, 2018
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre studyPaul M Barr, Hongli Li, W Richard Burack, et al.
American Journal of Hematology|December 22, 2017
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806Daniel O Persky, Hongli Li, Lisa M Rimsza, et al.
Haematologica|February 24, 2018
Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohortLisa M Rimsza, Hongli Li, Rita M Braziel, et al.
Haematologica|July 14, 2022
Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001Deborah M Stephens, Hongli Li, Louis S Constine, et al.
The Oncologist|July 27, 2019
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet NeedsMatthew J Matasar, Stefano Luminari, Paul M Barr, et al.
Blood|November 15, 2014
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313Daniel O Persky, Thomas P Miller, Joseph M Unger, et al.
Haematologica|April 10, 2010
Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphomaChristopher J Stasik, Hiroaki Nitta, Wenjun Zhang, et al.
Leukemia & Lymphoma|January 14, 2016
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520Soham D Puvvada, Hongli Li, Lisa M Rimsza, et al.
Journal of the National Cancer Institute|January 2, 2017
Hodgkin Lymphoma: Current Status and Clinical Trial RecommendationsCatherine S Diefenbach, Joseph M Connors, Jonathan W Friedberg, et al.
Blood|June 12, 2008
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOPLisa M Rimsza, Michael L Leblanc, Joseph M Unger, et al.
Pageof 5